BRCA mutations and outcome in epithelial ovarian cancer (EOC): Experience in ethnically diverse groups

T. Safra, W. C. Lai, L. Borgato, M. O. Nicoletto, T. Berman, E. Reich, M. Alvear, I. Haviv, F. M. Muggia

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Epithelial ovarian cancer (EOC) patients with BRCA mutations have better prognosis than nonhereditary cases matched for histology and stage and age at diagnosis, especially Ashkenazi Jews (AJ). Materials and methods: We retrospectively reviewed data on 700 highly ethnically heterogeneous patients diagnosed with stage Ic-IV EOC and evaluated for BRCA status between 1995 and 2009 in American, Israeli, and Italian medical centers. Results: The ethnicities of the 190 patients (median age 55.5 years, range 31-83 years) were AJ, Jewish non-Ashkenazi, Caucasian, African-American, Hispanic, or unknown. Ninety were BRCA1/2 carriers (71 BRCA1 and 19BRCA2). The most common mutations in AJ and non-AJ origins were 185delAG and 6174delT. Non-Jewish Caucasians exhibited the widest variation (>20 mutation subtypes). BRCA carriers had significantly prolonged median overall survival (93.6 months) compared with noncarriers (66.6 months; 95% confidence interval 44.5-91.7, P = 0.0081). There was no difference in progression-free survival. Conclusions:Our data demonstrate awide varietyof BRCA mutations in a highly ethnically diverse EOC population, and confirm that EOC BRCA mutation carriers have better prognosis with longer median survival than patients with nonhereditary disease. The contribution of unclassified BRCAvariants to cancer etiology remains undetermined.

Original languageEnglish
Article numbermdt315
JournalAnnals of Oncology
Volume24
Issue numberSUPPL.B
DOIs
Publication statusPublished - 2013

Fingerprint

Jews
Mutation
Survival
Hispanic Americans
African Americans
Disease-Free Survival
Histology
Ovarian epithelial cancer
Confidence Intervals
Population
Neoplasms

Keywords

  • BRCA
  • Ethnic variation
  • Ovarian cancer
  • Prognosis
  • Unclassified mutations

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

BRCA mutations and outcome in epithelial ovarian cancer (EOC) : Experience in ethnically diverse groups. / Safra, T.; Lai, W. C.; Borgato, L.; Nicoletto, M. O.; Berman, T.; Reich, E.; Alvear, M.; Haviv, I.; Muggia, F. M.

In: Annals of Oncology, Vol. 24, No. SUPPL.B, mdt315, 2013.

Research output: Contribution to journalArticle

Safra, T, Lai, WC, Borgato, L, Nicoletto, MO, Berman, T, Reich, E, Alvear, M, Haviv, I & Muggia, FM 2013, 'BRCA mutations and outcome in epithelial ovarian cancer (EOC): Experience in ethnically diverse groups', Annals of Oncology, vol. 24, no. SUPPL.B, mdt315. https://doi.org/10.1093/annonc/mdt315
Safra, T. ; Lai, W. C. ; Borgato, L. ; Nicoletto, M. O. ; Berman, T. ; Reich, E. ; Alvear, M. ; Haviv, I. ; Muggia, F. M. / BRCA mutations and outcome in epithelial ovarian cancer (EOC) : Experience in ethnically diverse groups. In: Annals of Oncology. 2013 ; Vol. 24, No. SUPPL.B.
@article{d25cadc1246d4376b23ae7337b9a4a8f,
title = "BRCA mutations and outcome in epithelial ovarian cancer (EOC): Experience in ethnically diverse groups",
abstract = "Background: Epithelial ovarian cancer (EOC) patients with BRCA mutations have better prognosis than nonhereditary cases matched for histology and stage and age at diagnosis, especially Ashkenazi Jews (AJ). Materials and methods: We retrospectively reviewed data on 700 highly ethnically heterogeneous patients diagnosed with stage Ic-IV EOC and evaluated for BRCA status between 1995 and 2009 in American, Israeli, and Italian medical centers. Results: The ethnicities of the 190 patients (median age 55.5 years, range 31-83 years) were AJ, Jewish non-Ashkenazi, Caucasian, African-American, Hispanic, or unknown. Ninety were BRCA1/2 carriers (71 BRCA1 and 19BRCA2). The most common mutations in AJ and non-AJ origins were 185delAG and 6174delT. Non-Jewish Caucasians exhibited the widest variation (>20 mutation subtypes). BRCA carriers had significantly prolonged median overall survival (93.6 months) compared with noncarriers (66.6 months; 95{\%} confidence interval 44.5-91.7, P = 0.0081). There was no difference in progression-free survival. Conclusions:Our data demonstrate awide varietyof BRCA mutations in a highly ethnically diverse EOC population, and confirm that EOC BRCA mutation carriers have better prognosis with longer median survival than patients with nonhereditary disease. The contribution of unclassified BRCAvariants to cancer etiology remains undetermined.",
keywords = "BRCA, Ethnic variation, Ovarian cancer, Prognosis, Unclassified mutations",
author = "T. Safra and Lai, {W. C.} and L. Borgato and Nicoletto, {M. O.} and T. Berman and E. Reich and M. Alvear and I. Haviv and Muggia, {F. M.}",
year = "2013",
doi = "10.1093/annonc/mdt315",
language = "English",
volume = "24",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL.B",

}

TY - JOUR

T1 - BRCA mutations and outcome in epithelial ovarian cancer (EOC)

T2 - Experience in ethnically diverse groups

AU - Safra, T.

AU - Lai, W. C.

AU - Borgato, L.

AU - Nicoletto, M. O.

AU - Berman, T.

AU - Reich, E.

AU - Alvear, M.

AU - Haviv, I.

AU - Muggia, F. M.

PY - 2013

Y1 - 2013

N2 - Background: Epithelial ovarian cancer (EOC) patients with BRCA mutations have better prognosis than nonhereditary cases matched for histology and stage and age at diagnosis, especially Ashkenazi Jews (AJ). Materials and methods: We retrospectively reviewed data on 700 highly ethnically heterogeneous patients diagnosed with stage Ic-IV EOC and evaluated for BRCA status between 1995 and 2009 in American, Israeli, and Italian medical centers. Results: The ethnicities of the 190 patients (median age 55.5 years, range 31-83 years) were AJ, Jewish non-Ashkenazi, Caucasian, African-American, Hispanic, or unknown. Ninety were BRCA1/2 carriers (71 BRCA1 and 19BRCA2). The most common mutations in AJ and non-AJ origins were 185delAG and 6174delT. Non-Jewish Caucasians exhibited the widest variation (>20 mutation subtypes). BRCA carriers had significantly prolonged median overall survival (93.6 months) compared with noncarriers (66.6 months; 95% confidence interval 44.5-91.7, P = 0.0081). There was no difference in progression-free survival. Conclusions:Our data demonstrate awide varietyof BRCA mutations in a highly ethnically diverse EOC population, and confirm that EOC BRCA mutation carriers have better prognosis with longer median survival than patients with nonhereditary disease. The contribution of unclassified BRCAvariants to cancer etiology remains undetermined.

AB - Background: Epithelial ovarian cancer (EOC) patients with BRCA mutations have better prognosis than nonhereditary cases matched for histology and stage and age at diagnosis, especially Ashkenazi Jews (AJ). Materials and methods: We retrospectively reviewed data on 700 highly ethnically heterogeneous patients diagnosed with stage Ic-IV EOC and evaluated for BRCA status between 1995 and 2009 in American, Israeli, and Italian medical centers. Results: The ethnicities of the 190 patients (median age 55.5 years, range 31-83 years) were AJ, Jewish non-Ashkenazi, Caucasian, African-American, Hispanic, or unknown. Ninety were BRCA1/2 carriers (71 BRCA1 and 19BRCA2). The most common mutations in AJ and non-AJ origins were 185delAG and 6174delT. Non-Jewish Caucasians exhibited the widest variation (>20 mutation subtypes). BRCA carriers had significantly prolonged median overall survival (93.6 months) compared with noncarriers (66.6 months; 95% confidence interval 44.5-91.7, P = 0.0081). There was no difference in progression-free survival. Conclusions:Our data demonstrate awide varietyof BRCA mutations in a highly ethnically diverse EOC population, and confirm that EOC BRCA mutation carriers have better prognosis with longer median survival than patients with nonhereditary disease. The contribution of unclassified BRCAvariants to cancer etiology remains undetermined.

KW - BRCA

KW - Ethnic variation

KW - Ovarian cancer

KW - Prognosis

KW - Unclassified mutations

UR - http://www.scopus.com/inward/record.url?scp=84886313748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886313748&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt315

DO - 10.1093/annonc/mdt315

M3 - Article

C2 - 24131973

AN - SCOPUS:84886313748

VL - 24

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL.B

M1 - mdt315

ER -